BRIEF-Cellectar Biosciences Gets Granted Orphan Drug Designation For CLR 131 To Treat Neuroblastoma
March 19 (Reuters) - Cellectar Biosciences Inc:
* CELLECTAR BIOSCIENCES GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT NEUROBLASTOMA
* ‍CELLECTAR EXPECTS TO INITIATE THIS STUDY DURING Q2 OF 2018​ Source text for Eikon: Further company coverage: